Table 4 Length of ICU and hospital stay according to reason for ICU admission
From: ICU admission for solid cancer patients treated with immune checkpoint inhibitors
Respiratory N = 66 | Colitis N = 14 | Cardiovascular N = 13 | Metabolic N = 11 | Neurological N = 6 | |
|---|---|---|---|---|---|
Time to ICU discharge (days) | 5 [3–11] | 4 [3–10] | 13 [8–17] | 3 [2–5] | 5 [3–12] |
Admission “likely” related to irAE | 7 [4–14] | 3 [3–5] | 4 [3–7] | 3 [3–5] | 8 [4–38] |
Admission “unlikely” related to irAE | 4 [2–8] | 4 [2–12] | 2 [1–4] | 2 [2–2] | 4 [2–6] |
ICU mortality | 19 (28) | 0 (0) | 0 (0) | 3 (27) | 1 (17) |
Admission “likely” related to irAE | 9 (47) | 2 (67) | 1 (100) | ||
Admission “unlikely” related to irAE | 10 (53) | 1 (33) | 0 (0) | ||
Time to hospital discharge (days) | 14 [7–19] | 14 [10–43] | 13 [8–17] | 8 [3–14] | 13 [12–20] |
Admission “likely” related to irAE | 14 [9–21] | 22 [9–48] | 13 [5–25] | 8 [5–8] | 13 [12–55] |
Admission “unlikely” related to irAE | 9 [5–17] | 12 [10–19] | 13 [9–15] | 10 [2–12] | 16 [12–20] |
Hospital mortality | 29 (44) | 2 (14) | 3 (23) | 3 (27) | 1 (17) |
Admission “likely” related to irAE | 12 (41) | 0 (0) | 0 (0) | 2 (67) | 1 (100) |
Admission “unlikely” related to irAE | 17 (59) | 2 (100) | 3 (100) | 1 (33) | 0 (0) |